Phaseline

Companies › Shanghai CureGene Pharmaceutical

Shanghai CureGene Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CG-0255 Besylate for Injection
Prodrug of active metabolite of clopidogrel with alternative activation pathway
–Phase 1Acute Coronary Syndromes (ACS)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07619885CG-0255 Besylate for InjectionPhase 1Acute Coronary Syndromes (ACS)CardiovascularDec 2026
NCT07619885CG-0255 Besylate for InjectionPhase 1Acute Coronary Syndromes (ACS)CardiovascularDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.